On March 31, 2016, the ALS Association announced the awarding of an ALS Association-Initiated Grant to Origent’s Chief Science Officer David Ennist, Ph.D. The grant will enable a research partnership with Cytokinetics Inc. to improve clinical trial design. The topic of Dr. Ennist’s project is “Prospective Validation of ALS Disease Models and Tools.”

The full press release is available on-line at PR Newswire.

Share This